Abstract
In the United States there are about 7,500 new cases of Hodgkin’s disease (HD) per year. The age distribution is bimodal in that the peak incidences are at approximately 25 and 80 years of age. HD usually presents as a localized lymph node enlargement and progresses in an orderly manner (contiguous rather than hematogenous dissemination). However, any organ, including the bone marrow, liver, lung, pericardium, pleura, skin, bone, and the central nervous system, can be involved. Patients may present with “B” symptoms (Table 1), pruritus, jaundice, ascites, and dysphagia. The fever may have a cyclic pattern, with several days of fever alternating with afebrile periods (Pel-Ebstein fever). Some patients with HD complain of alcohol-induced pain in areas of diseased lymph nodes. Laboratory abnormalities may include cytopenias, leukocytosis, eosinophilia, abnormal liver function tests, and increased erythrocyte sedimentation rate. Paraneoplastic manifestations associated with HD include lipoid (minimal change) nephrosis, demyelinating neuropathy, and cerebellar syndromes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
Hodgkin’s Disease
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484.
Leibenhaut MH, Hoppe RT, Efron B, Halpern J, Nelsen T, Rosenberg SA. Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin’s disease. J Clin Oncol 1989; 7: 81–91.
Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Hudson GV. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051–1054.
Lister TA, Crowther D. Staging for Hodgkin’s disease. Semin Oncol 1990; 17: 696–703.
Longo DL. The use of chemotherapy in the treatment of Hodgkin’ s disease. Semin Oncol 1990: 17: 716–735.
Mauch P, Tarbell N, Weinstein H, Silver B, Goffman T, Osteen R, Zajac A, Coleman CN, Canellos G, Rosenthal D. Stage IA and IIA supradiaphragmatic Hodgkin’s disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988: 6: 1576–1593.
van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, van Heerde P, Somers R. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 1994; 12: 312–325.
Non-Hodgkin’s Lymphoma
Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N EnRl J Med 1993; 328: 1002–1006.
Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.
Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.
Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med 1984; 311: 1471–1475.
McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD. Effective treatment of smallnoncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol 1991; 9: 941–946.
Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’ lymnhoma. N En gl .11ed 1998 339 21–26
Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M, Laporte J-P, Maraninchi D, Pico J, Bosly A, Anderson C, Schots R, Biron P, Cabanillas F, Dicke K. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987; 316: 1493–1498.
The International Non-Hodgkin’ s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993; 329: 987–994.
The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 2112–2135.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Habermann, T.M. (2001). Hodgkin’s Disease and Non-Hodgkin’s Lymphoma. In: Tefferi, A. (eds) Primary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-228-9_17
Download citation
DOI: https://doi.org/10.1007/978-1-59259-228-9_17
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-122-6
Online ISBN: 978-1-59259-228-9
eBook Packages: Springer Book Archive